Solasia Pharma K.K. provided consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue in the range of ¥2,300 million to ¥3,800 million, operating loss in the range of ¥1,100 million to operating profit of ¥150 million, loss in the range of ¥1,200 million to profit of ¥50 million, basic loss per share in the range of ¥8.02 to basic earnings per share of ¥0.33.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 JPY | -3.70% | -3.70% | -42.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.22% | 31.66M | |
-2.32% | 92.59B | |
+3.16% | 41.43B | |
-11.10% | 33.49B | |
+53.68% | 25.06B | |
-9.41% | 12.77B | |
-12.25% | 11.58B | |
-44.00% | 11.35B | |
+5.69% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022